Literature summary for 3.4.17.20 extracted from

Erdogan, M.; Karadeniz, M.; Alper, G.E.; Tamsel, S.; Uluer, H.; Caglayan, O.; Saygili, F.; Yilmaz, C.
Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome (2008), Exp. Clin. Endocrinol. Diabetes, 116, 143-147.

Search for more literature for 3.4.17.20

Application

Application	Comment	Organism
medicine	no significant difference in lipid parameters is determined between patients with polycystic ovary syndrome and healthy controls. In addition, no difference in CIMT measurements and TAFI levels between patients with polycystic ovary syndrome and healthy controls is shown	Homo sapiens

Protein Variants

Protein Variants	Comment	Organism
additional information	circulating TAFI levels and carotid intima-media thickness (CIMT) in polycystic ovary syndrome (PCOS) patients and control subjects are analysed. Plasma TAFI levels are similarly in polycystic ovary syndrome patients compared with healthy controls. No difference is observed in the combined IMT among the studied groups	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	-	-

Source Tissue

Source Tissue	Comment	Organism	Textmining
blood plasma	-	Homo sapiens	-

Synonyms

Synonyms	Comment	Organism
TAFI	-	Homo sapiens
thrombin-activatable fibrinolysis inhibitor	-	Homo sapiens

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)